

A woman with long brown hair, wearing a blue denim overall dress over a pink and blue striped top, stands in a grassy field with trees in the background. She has a tattoo on her left shoulder and a white glucose sensor on her upper arm. The text '2023' is in the bottom right, and 'Our Impact' is in large white letters at the bottom.

2023

Our Impact

Contents

Foreword from our Chief Executive	03
Our impact in numbers	04
Our strategy	05
Goal 1: Drive research to cure, treat and prevent type 1	07
Goal 2: Accelerate access to type 1 technologies and medicines	15
Goal 3: Support people living with type 1	21
Fundraising activity and campaigns	27
You make it possible	32

Cover image: Jharna Kumawat, JDRF supporter who lives with type 1

This page image: JDRF Rufus bear



“From campaign success increasing access to life-changing treatments to paving the way for ground-breaking research in the UK and beyond, JDRF has been at the forefront.”

Karen Addington
Chief Executive Officer

Foreword from our Chief Executive

This past year, we are proud to have transformed the UK research and treatment landscape for people living with type 1 diabetes.

Through our policy work, we are delighted that over the next five years the NHS will start offering hybrid closed loop (HCL) technology to the majority of people living with type 1 in England and Wales. HCL was approved in Scotland in 2022 and we are working towards gaining access for people in Northern Ireland. This is the biggest treatment breakthrough since the discovery of insulin and the technology is transforming the lives of people with type 1.

We launched the first Type 1 Diabetes Grand Challenge projects together with our partner, Diabetes UK, this year. Through this partnership, funded by the Steve Morgan Foundation, and thanks to the generosity of Steve and Sally Morgan, we are harnessing the power of collaboration.

Image: Karen Addington, CEO, JDRF UK



Our research projects will fast-track discoveries that we believe will lead to life-changing new treatments and ultimately potential cures for type 1. We believe the Grand Challenge will drive forward type 1 research at pace in the UK and internationally.

The results of our global research and advocacy this year have been profound. An example of this is the international PROTECT study which found that the drug teplizumab can slow progression of type 1 in people newly diagnosed. With further ongoing research, this study offers a real opportunity to ease significantly the management of type 1 and reduce the risk of complications.

We also launched the Global Advocacy Programme, working with partners in India to increase access to diagnosis and essential type 1 treatment. Together, with our global affiliates, we are striving to find ways to cure, treat and prevent type 1 – and improve lives.

The demand for our information and support resources continues to increase, reflecting our key role in providing trusted information to people living with type 1. The design and content of our new website makes it easier to find information and support people to live well with type 1.

We are very grateful to you, our supporters. Your generosity has enabled us to progress our mission this year. You should take immense pride in all the life-changing breakthroughs you have enabled in 2023.



Karen Addington
Chief Executive Officer

Our impact in numbers



£1,669,000

raised for UK research projects from July-June 22/23



761,195

visits to the JDRF website



2,900

registrations for our community events

Our Strategy

We are in the final year of our ambitious three-year strategy and have made huge strides in our mission towards a world without type 1. We couldn't have done any of this without the dedication of our supporters.

When we work together, we can achieve incredible things.

Image: Seun Alaba, JDRF supporter who lives with type 1



GOAL 1

Drive research to cure, treat and prevent type 1



GOAL 2

Accelerate access to type 1 technologies and medicines




GOAL 3

Support people living with type 1

"We can't wait to see the results of this vital research to transform beta cell therapy, create new improved forms of insulin, and tackle the immune reaction, which is driving type 1. This research is bringing people living with type 1 a step closer to a life free from burden."

Rachel Connor, Director of Research Partnerships at JDRF UK





Goal 1

Drive research to cure, treat and prevent type 1

This year marked a transformative shift in type 1 research, driven by our collaborations with researchers, scientists, and partner organisations across the world. Together, we are not just envisioning a better future for those living with type 1; we are making it possible.



£50,000,000

committed to type 1 research from the The Steve Morgan Foundation

THE FUTURE FOR TYPE 1 STARTS NOW

A transformative collaboration

In 2022, we launched the £50 million Type 1 Diabetes Grand Challenge in partnership with the Steve Morgan Foundation and Diabetes UK. The Grand Challenge aims to create transformative change that will drive us forward towards cures for type 1.

We are exploring the root causes of type 1 and pioneering the development of potentially life-changing new forms of insulin. Over the next five years, we will manage the £20 million allocated to these priorities.

Together with the Steve Morgan Foundation and Diabetes UK, JDRF is delivering progress at pace:

- **March 2023:** Three senior research fellows were awarded grants to increase the ability of people with type 1 to preserve their beta cells or accept the replacement of insulin-producing beta cells
- **May 2023:** We convened an international research symposium to identify potential research for novel, more adaptive forms of insulin
- **December 2023:** £13 million of funding was awarded to six research projects with a focus on helping people make their own insulin and stopping the immune attack

Image: JDRF research lab

ELSA study to identify early signs of diabetes in children for over 8,000 families

Three in 1,000 children in the UK are experiencing the early stages of type 1. In November 2022, through a funding partnership with Diabetes UK, we launched the ELSA study, to test and identify children aged 3 – 13 who are at the early stages of developing type 1.

As well as ensuring an early and safer diagnosis, it also enables those identified as developing type 1 to explore access to clinical trials, testing the newest

innovations in preventing or delaying type 1. Thanks to our research, a new immunotherapy, teplizumab has been developed which can delay the onset of type 1. This treatment has been approved in the USA, which will help enable NHS approval in the UK. By identifying children at the early stages of developing type 1, a treatment like teplizumab can delay the onset and pave the way for a childhood free from type 1.



Cerilyn and Alys' Story

Cerilyn signed Alys and her sister up for the ELSA study as both their dad and grandad live with type 1. Detecting type 1 early was the main reason they decided to take part.

Shortly after signing up for the study, they received a test kit and completed a finger prick test. Then, two weeks later, a doctor from the ELSA team contacted Cerilyn and told their family that Alys had tested positive for proteins called autoantibodies, which showed that she was developing the condition.

Having advanced warning that Alys will develop type 1 has given Cerilyn and her family precious time to prepare for managing the condition.

“The ELSA study has given Alys the best possible start to type 1” Cerilyn

Image: Alys and Rufus the bear

Ground-breaking clinical trials using existing drugs to treat type 1

We awarded a £1.5 million grant to researchers at the University of Dundee to support a UK-wide clinical trial that could potentially advance a new life-saving treatment for people with type 1 and heart failure.

The SOPHIST trial will study the effect of a drug called sotagliflozin, which belongs to a class of prescription medicines called SGLT2 inhibitors. These are used with diet and exercise to lower blood sugar and improve heart and kidney health in adults with type 2 diabetes. SGLT2 inhibitors have been tested for glucose control in people with type 1, but this is the first large trial globally studying SGLT2 inhibitors in people with type 1 and heart failure.

Our international research trial - The BANDIT also highlights the value of identifying existing immunotherapy treatments that are already approved for different autoimmune conditions. In this trial, baricitinib, a drug often prescribed for rheumatoid arthritis and alopecia preserved the body's insulin production and suppressed the progression of type 1 in people newly diagnosed with the condition.



“If we do find that SGLT2 inhibitors improve quality of life compared to placebo in people with type 1 and heart failure, then this could have a significant impact on clinical practice worldwide, potentially changing treatment guidelines.”

Dr Ify Mordi, lead researcher
of the SOPHIST trial

Image: A large centrifuge in a JDRF research lab



New therapies to prevent type 1 in young children

One of our studies in partnership with Diabetes UK, has identified genes involved in immune responses, which are activated specifically in people who develop type 1 at a young age. The signalling pathways linked to these genes are potential targets for new therapies to prevent type 1 in young children.

“Detecting these immune system signals in people already identified from screening programmes as being at risk of diabetes may be indicative of early onset type 1. The biological pathways these signals use are potential targets for treatments to slow or block the progression of type 1.”

Dr Michael Christie, Lead Investigator

Revolutionising the approach to autoimmune conditions

This year we launched The Connect Immune Research Lab Placement Grants, which place early career researchers at another laboratory to learn more about other autoimmune condition research. This helps us to find connections between different conditions.

Two new organisations joined the Connect Immune Research Partnership this year - myaware and Juvenile Arthritis Research. Growing the pool of experts dedicated to finding the root cause of autoimmune conditions accelerates us towards new ways of treating the conditions.



Image: Research assistant, at King's College London

Her Majesty the Queen tours laboratory aiming to stop type 1 in its tracks

In June, we invited Our President, Her Majesty The Queen to join us for a lab visit at University College London with Professor Lucy Walker. During the visit, The Queen learned more about our research into autoimmune conditions.



Image: Her Majesty The Queen visiting UCL

“We were delighted to welcome Her Majesty The Queen and showcase the innovative work being carried out thanks to our Connect Immune Research Partnership. We are incredibly grateful for The Queen’s support since June 2012 as our President and for helping us raise awareness about the importance of research in bringing us closer to a cure.”

Karen Addington, CEO, JDRF UK



Funding innovative research

Our latest Small Grant Awards have been given to three researchers who are contributing to important areas of type 1 research:


£54,200

awarded through our Small Grant Awards



Dr. Joanne Boldison

is investigating the role of immune cell interactions in type 1 for potential targeted treatments



Dr. Fiona Docherty

aims to grow high-functioning insulin-producing beta cells, potentially advancing clinical trials for type 1



Dr. Nicholas Thomas

plans to follow up with 850 individuals diagnosed with diabetes three years ago, studying the impact of C-peptide tests on diagnosis and treatment



Image: Researcher working under a microscope in a JDRF lab

Slowing the progression of type 1


Approved by the US in November 2022, teplizumab is the first disease-modifying drug licensed for type 1. It's an immunotherapy drug, that can delay type 1 by up to three years and directly interferes with the immune attack.

A new JDRF internationally funded study, known as The PROTECT study, suggests that teplizumab can preserve beta cell function in people newly diagnosed. It found that the C-peptide levels,

which is a measure of the amount of insulin a person can make, declined more slowly in the people who received teplizumab than those who didn't receive it.

The potential impact of teplizumab for those newly diagnosed could be revolutionary. By slowing the progression of type 1, it enables newly diagnosed individuals to sustain insulin production for longer, significantly easing the management of type 1 and reducing the risk of complications.





2023 marked a new era for type 1 treatments. With hybrid closed loop technology set to become widely available across England, Wales and Scotland we have made significant developments in providing technology treatments to improve the lives of those living with type 1.

Image: A woman with type 1 using a flash glucose monitor



Goal 2 Accelerate access to type 1 technologies and medicines

“In type 1 medical research we stand on the shoulders of the Nobel Prize-winning giants, Professors Banting and Macleod for their discovery of insulin. Hybrid closed loop defines a new era for medicine.”

Hilary Nathan, Policy Director at JDRF UK

A NEW ERA FOR TYPE 1

The biggest treatment breakthrough for type 1 since the discovery of insulin

Hybrid closed loop (HCL) technology, also known as the artificial pancreas, is set to be rolled out on the NHS in England and Wales following Scotland's lead, transforming the lives of many people living with type 1, following the publication of landmark NICE guidance.

The incredible generosity of our supporters has enabled us to invest £115 million in international research and clinical trials to develop HCL over almost 20 years. The UK is now a global leader in making HCL available free at the point of need, and other high-income countries will now be looking at our achievements and following in our footsteps.

All children and young people, women who are pregnant or planning a pregnancy, and people who already have an insulin pump will be the first to be offered HCL as part of a five-year roll-out plan.

“I felt more trust in my own body”

Nina Willer started using hybrid closed loop during her second pregnancy.

“During my first pregnancy eight years ago, I used finger prick testing. I felt like I was constantly chasing my tail trying to keep on top of the highs and lows. During my second pregnancy, I started on hybrid closed loop at eight weeks and everything changed. Every single day for that pregnancy and since, I have woken up in target. I have had a huge reduction in hypos. I felt more trust in my own body for the first time in ages. I still have to think about my diabetes, but for once it is not at the forefront of my mind all day every day. For me, it is like being on autopilot. I am forever grateful for the care I received and the technology that was made available to me, and excited for the future of diabetes!”

Image: Nina Willer



JDRF-funded researcher wins prestigious award at Europe’s largest diabetes conference

Professor Roman Hovorka won a major award, the EASD- Novo Nordisk Foundation Diabetes Prize for Excellence, at Europe’s largest diabetes conference this year, for his research on hybrid closed loop technology. Thanks to our generous supporters, we funded Roman for 12 years to create the world’s first licensed hybrid closed loop app for people living with type 1.

Image: Aaron Kowalski (JDRF International CEO), Karen Addington (JDRF UK CEO) and Professor Roman Hovorka

JDRF IN THE MEDIA

Raising awareness and impacting lives



We secured coverage in **The Mail on Sunday** with a two-page printed spread for the HCL NICE announcement. It included quotes and a case study provided by JDRF, spreading awareness of HCL and type 1.



The Mail Online, The Guardian, The Sun, The Telegraph, The Independent and **The Radio Four Today Programme** covered the HCL NICE announcement, and JDRF's commentary. **The Guardian** and **The Sun** included this quote from Karen Addington, CEO - *"It's a beautiful algorithm which will save lives and heartbreak."*



Professor Partha Kar - NHS England's National Specialty Advisor for Diabetes, spoke about HCL on **Radio Four's Today Programme** and said that *"JDRF has sponsored the research and evidence and has been a driving light."*



Overall from this media coverage, we reached a vast audience. **600,000 for print coverage, 91.2 million for online readership, and 5.6 million for radio.**

"JDRF has sponsored the research and evidence and has been a driving light."

Professor Partha Kar,
NHS England's
National Specialty
Advisor
for Diabetes

Championing international advocacy

In 2022, we launched the first Type 1 Diabetes Index, a tool that measures the global impact of type 1 in every country around the world. This year, we have used this tool to help positively impact the lives of people living with type 1.

Using the data, this year JDRF's Global Advocacy team launched a new programme in India together with Professor Partha Kar, NHS England's National Specialty Advisor for Diabetes, to improve access to diagnosis and treatments which will improve longevity and quality of life.

This work is supported by The Impatient Network, a partnership of grassroots and community-based diabetes advocates in India. The Impatient Network is working with JDRF, the clinical community, and partner organisations to provide access to peer-led education, support services, and resources that will help to combat stigma and raise awareness of type 1 in India.



Image: The launch of the Impatient Network

Our promise to raise awareness of type 1 disordered eating

We created a major national and international spotlight on improving care and support for people living with type 1 diabetes disordered eating (T1DE). Over the last two years, we have provided Secretariat support for the Parliamentary Inquiry into Type 1 and Disordered Eating, co-chaired by JDRF's Global Research Ambassador, the Right Honourable Theresa May MP, and Sir George Howarth MP.

We set the scope of the inquiry sessions, convened the witnesses, developed the recommendations and authored the subsequent inquiry report. The inquiry is the first of its kind to assess the causes and incidence of T1DE, the gaps in research, diagnosis, and clinical practice, and the impact on people living with T1DE.

T1DE can be a severe and fatal complication of type 1. Research shows that around a third of people living with type 1 experience a form of disordered eating because of the effects of food intake on blood glucose levels.

The report aims to raise mass awareness of T1DE. The objective of the report is to reframe the priorities for local health commissioners to fund more evidence-based, integrated services that will help people with T1DE recover faster and will help save the NHS money from a reduction in emergency admissions and long-term complications.

“Imagine you are a young person whose concern about their body image leads them to an unhealthy relationship with food. You are encouraged to eat several times a day. Then imagine that you are also a type 1 diabetic who has to inject insulin every time you eat, knowing that insulin can lead to you putting on weight. Finally imagine that the support you receive from the NHS treats each condition separately and no one seems able to treat you as a whole person, understanding your seemingly conflicting needs.”

The Right Honourable Theresa May MP, our
Global Research Ambassador

We are here for you from
when you first hear the
words type 1 diabetes.





Goal 3

Support people living with type 1

"I think your in-person events are invaluable. When I look back on the events that I have attended, each one marks a turning point in the development of my knowledge and confidence with taking care of my type 1."

Cardiff Discovery Day attendee

**WE SUPPORT, WE LISTEN,
WE EMPOWER**

Bringing the type 1 community together

This year we continued to connect with people living with type 1 through our in-person and virtual community events. These events focused on topics such as mental health, physical activity, and other important subjects.



3,800

**children in England
diagnosed with type
1 this year**



30%

**increase on
pre-pandemic
years**

Image: Mary Murphy, Database
Support Officer at JDRF UK

Our commitment to making information accessible for all

Thanks to the Steve Morgan Foundation and the Government's Community Match Challenge grant, we launched a new website built on extensive research into what people with type 1 need. We focused on making our web content and resources more tailored to what people need at different ages and stages of life, as well as being more inclusive, accessible, and diverse.

"My brother's granddaughter has recently been diagnosed with type 1 and her parents are understandably in shock. I've spent the last half hour going through your wonderful website and I want to congratulate you on the caring, informative approach you have taken."

Jeni Scott Dalgeish, JDRF Supporter

Whilst we know there is still more to do, around half of our website stories about living with type 1 reflect diverse backgrounds, including cultural, socioeconomic, disability, and LGBTQIA+ perspectives.

Image: A JDRF Discovery Day, Belfast

"Thank you very much for this event - it has been absolutely brilliant and so informative and also very comforting for a newly diagnosed person like me!"

Females and Type 1 Virtual
Discovery Day attendee



You said - we did

We pride ourselves on providing information that is relevant and valuable to people living with type 1. So, we sent out a social media survey to find out what topics were most important to our community. We

had a great response, with subjects including mental health, physical activity, and education, enabling us to provide a space where people could hear each other's stories and support each other on the issues that matter.



2,900

**registrations for
our events**



11

**community events held
throughout the UK**

Impacting children's lives for the better

Our information and support resources for newly diagnosed children continue to be in high demand, with NHS paediatric clinics across the UK ordering over 5,000 KIDSACs. The number of NHS orders demonstrates the value healthcare professionals place on our information to support newly diagnosed children and their families.

"You guys are amazing. The wealth of information you gave to us when my son was first diagnosed was invaluable. It was like a light in a dark, confusing place."

Ingrid, parent of a child living with type 1



Life-changing information

Throughout 2023, we continued to provide trusted information and support to people living with type 1.

“The Adult Toolkit covers everything I can think of that I would want to know about at diagnosis and more for the future.”

Chris, an adult living with type 1

11,465 families supported with newly diagnosed resources

4,288 adults supported with newly diagnosed resources



5,052 KIDSACs distributed to newly diagnosed young people

41,534 support resources given to people with type 1 and healthcare professionals

26,841 people accessed our schools e-learning module



The impact of Rufus

Jay James, singer in the band The Overtones, and music manager, was introduced to JDRF this year when his son Franklin was diagnosed with type 1.

Jay was introduced to JDRF through Rufus the bear – when his music client Tom Ball, gave Franklin his own Rufus, which Franklin immediately loved.

Since then, Jay has played a huge part in supporting JDRF. He's spoken at our Discovery Days, was the face of our Christmas Appeal and Jay's band, The Overtones, also released a Christmas single and donated half the proceeds to JDRF. Jay also launched My Diabetes Story – a community aimed to empower everyone touched by diabetes.



“We’ve been blown away by all the support JDRF and the type 1 community has given us. We thought we were going to be on our own dealing with such a huge challenge but that couldn’t be further from the truth.”

Jay James, parent of Franklin living with type 1

Image: Jay James and his family



In 2023 we came together as a community. From our Patrons and Accelerator Programme to the London Marathon, One Walk, and Christmas Appeal, every supporter has made a positive impact to the lives of people living with type 1.

Image: London Marathon

Our fundraising activity and campaigns



£1 million

in donations from our Patrons and members of our Accelerator Programme



WHEN WE WORK TOGETHER, WE ACHIEVE INCREDIBLE THINGS

Supporting our mission

None of the research and technology breakthroughs this year would have been possible without the commitment and generosity of you, our supporters. You have enabled us to continue to drive our mission to cure, treat and prevent type 1.

Major Giving

We want to say thank you to our Patrons and members of our Accelerator Programme whose gifts transform the landscape for type 1. They make ambitious new projects possible, enable us to achieve substantial progress in our research, and significantly advance our understanding of the condition.

“Our daughter, Annabel, was diagnosed with type 1 at age two. Within days we contacted JDRF who were incredibly supportive. The determination of JDRF to find a cure has inspired us to support them through the Accelerator Programme.

We are also excited to support the Connect Immune Research initiative as Annabel was diagnosed with Juvenile Idiopathic Arthritis when she was seven.

We hope that our support for JDRF will result in further breakthroughs and one day, a cure.”

- Clare, Accelerator Programme member

Image: Researchers in the lab at the University of Exeter.



The transformative power of fundraising

Over **3,000** people took part in our fundraising events in 2023



London Marathon

Amount raised:

£433,000

Number of participants:

190

One Walk

Amount raised:

£179,000

Number of participants:

1,509

Tri for Type 1

Amount raised:

£46,000

Number of participants:

318

Christmas Appeal

Amount raised:

£125,000

Christmas Carol Concert

Amount raised:

£55,000

“You gave me the experience of a lifetime that I will never forget. Raising money for your organisation was an absolute privilege!”

Tim, 2023 London Marathon runner

The transformative power of fundraising

428 people

organised a fundraiser
for JDRF, raising

£292,583

1,088 people

played the lottery with
JDRF in 2023

9,228

people donated to
JDRF, including

1,300

donors who made their
first gift to JDRF ten
years ago or more and

3,480

first-time donors



Corporate Partners

We rely on significant funding and support from our corporate partners and are grateful to all our corporate partners this year for helping us to continue to work towards our mission goals.

The Syncona Foundation, the charitable giving arm of Syncona Ltd, has been supporting JDRF for ten years with a cumulative donation of nearly **£1 million since 2013**. We are extremely grateful to The Syncona Foundation for its ongoing support.



Reaching more people with type 1

This year, through our campaigns, we aimed to promote and raise awareness of JDRF to people affected by type 1 and to drive traffic to our new website. We wanted to raise awareness of our impact through the information and guidance we provided and through the work we have done to bring hybrid closed loop to reality.

We reached approximately

558,000

people with our adverts and content



100,000

followers across our social media channels

542,000

new people visited our website

8,172,731

people saw our social content this year, of whom

345,910

interacted with it.



Triumphs in the digital realm

We achieved a significant social media milestone in 2023: We reached a combined number of 100,000 followers across our four JDRF UK social media channels, including Facebook, Instagram, X, and LinkedIn. This is an increase of **6,822** followers over the last year.

You make it possible

“2023 has been a monumental year for type 1, but none of the incredible achievements would have been possible without our supporters. Your generosity and unwavering support have been the driving force behind every breakthrough and together, we are getting ever closer to finding a cure. Thank you for championing our mission – we couldn’t do it without you.”

Terence Lovell, Fundraising and Engagement Director at JDRF UK

OUR ACCELERATOR PROGRAMME MEMBERS

- Dominic Christian and Kate Birch
- Lincoln Benet
- Niall Curran and Sue Reid
- Patrick and Jane Kennedy
- Rosemary, Gordon and Cameron Fuller
- The Claringbull Family
- The Haywood Family
- The Manktelow Family
- The Pardoe Family
- The Right Honourable Theresa May MP
- The Sethia Family
- The Wilkinson Family
- The Zhao Family
- Wilson Leech



Image: Steve and Sally Morgan, founders of The Steve Morgan Foundation

Image: Bernie Warren, JDRF supporter living with type 1

CORPORATES

- Abbott Diabetes Care UK
- Advanced Therapeutics UK Ltd
- Air Liquid Healthcare Ltd
- Clover HR Ltd
- Dexcom UK Distribution Ltd
- Dextro Energy GmbH
- Ford Motor Company Ltd
- Hoban Waste Management
- Insulet International Ltd
- Lansons Ltd
- Lilly UK
- Medtronic Ltd
- Medtrum Ltd
- Menarini Diagnostics Ltd
- Sanofi UK
- The Syncona Foundation
- Ypsomed Ltd



And thank you to all our Patrons for their generous investment in our work:
www.jdrf.org.uk/philanthropy

TRUSTS

- Alexander Moncur Trust
- Beefy's Charity Foundation
- First Island Trust
- Hugh Fraser Foundation
- Peter John Foord Charitable Trust
- The Cadogan Charity
- The Elizabeth & Prince Zaiger Trust
- The Michael Lewis Foundation
- The Shanley Foundation
- The Steve Morgan Foundation
- The Valiant Charitable Trust
- TIOC Foundation



VOLUNTEERS

Volunteers are instrumental in helping us achieve our mission. In 2023, over 500 people, and 88 Youth Ambassadors generously offered their support, and we are grateful to all our dedicated supporters. Our Board Directors and scientific advisors freely give their time and are also an integral part of our team.

Our volunteer panel

Our Insight and Experience Panel continued to grow this year and now has 180 people with lived experience of type 1 supporting our work.

Image: Jon, JDRF supporter and volunteer.

We work with a range of dedicated corporate partners, trusts, foundations and philanthropists, and offer multiple opportunities to get involved in supporting type 1 research.

To find out how you can help, please contact us on:

supportercare@jdrf.org.uk

Image: Researchers Professor Sarah Richardson, Dr Ana Cruz, and Dr Paul Weightman-Potter at a JDRF funded research lab



We are JDRF, the leading global type 1 diabetes charity.

We improve lives today and tomorrow by accelerating life-changing breakthroughs to cure, treat and prevent type 1 diabetes and its complications.

Our reach extends across the globe – we are part of a global network of six affiliated international charities, all striving to find cures for type 1 diabetes.



CONTACT DETAILS

Address: **JDRF, 17/18 Angel Gate, City Road, London, EC1V 2PT**
Telephone: **020 7713 2030** Email: **info@jdrf.org.uk**

Copyright © 2024 | Juvenile Diabetes Research Foundation Ltd (JDRF) is a charity registered in England and Wales (No. 295716) and in Scotland (No. SC040123). Registered address: 17/18 Angel Gate, City Road, London, EC1V 2PT. Registered as a company limited by guarantee, in England and Wales (No 2071638).

